Elite Pharmaceuticals, Inc.
ELTP · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $84,044 | $56,625 | $34,155,114 | $32,262 |
| % Growth | 48.4% | -99.8% | 105,767.6% | – |
| Cost of Goods Sold | $43,957 | $30,268 | $17,561,093 | $17,467 |
| Gross Profit | $40,087 | $26,357 | $16,594,021 | $14,795 |
| % Margin | 47.7% | 46.5% | 48.6% | 45.9% |
| R&D Expenses | $7,965 | $6,883 | $6,200,163 | $4,051 |
| G&A Expenses | $9,229 | $6,965 | $5,122,272 | $4,478 |
| SG&A Expenses | $9,229 | $7,305 | $5,122,272 | $4,478 |
| Sales & Mktg Exp. | $0 | $340 | $0 | $0 |
| Other Operating Expenses | $3,292 | $1,380 | $1,595,584 | $1,195 |
| Operating Expenses | $20,486 | $15,568 | $12,918,019 | $9,725 |
| Operating Income | $19,600 | $10,789 | $2,025,111 | $5,071 |
| % Margin | 23.3% | 19.1% | 5.9% | 15.7% |
| Other Income/Exp. Net | -$19,653 | -$10,326 | $310 | $2,091 |
| Pre-Tax Income | -$52 | $463 | $3,985,874 | $7,162 |
| Tax Expense | $4,263 | -$19,646 | -$424,028 | -$1,736 |
| Net Income | -$4,315 | $20,109 | $4,409,902 | $8,898 |
| % Margin | -5.1% | 35.5% | 12.9% | 27.6% |
| EPS | -0.004 | 0.02 | 4.35 | 0.009 |
| % Growth | -120.2% | -99.5% | 49,331.8% | – |
| EPS Diluted | -0.004 | 0.02 | 4.35 | 0.007 |
| Weighted Avg Shares Out | 1,068,290 | 1,015,443 | 1,012,911 | 1,010,608 |
| Weighted Avg Shares Out Dil | 1,068,290 | 1,023,226 | 1,012,911 | 1,010,608 |
| Supplemental Information | – | – | – | – |
| Interest Income | $21 | $21 | $7 | $0 |
| Interest Expense | $772 | $589 | $1,113 | $192 |
| Depreciation & Amortization | $2,122 | $1,472 | $1,331 | $1,421 |
| EBITDA | $2,843 | $2,523 | $6,429 | $6,491 |
| % Margin | 3.4% | 4.5% | 0% | 20.1% |